Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Acq. announced

Comera Life Sciences Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "12 Gill Street Suite 4650 ∙ Woburn MA 01801"
10/02/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights – Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – –Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN, M..."
08/01/2023 8-K Quarterly results
05/19/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/12/2023 8-K Quarterly results
Docs: "Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights – Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 , highlighted by identification of a lead formulation – – Expanded Comera’s patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 — Comera Life Sciences Holdings, Inc. , a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ended March 31, 2023, and provided a business update. “..."
05/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/24/2023 8-K Investor presentation
Docs: "Corporate Presentation current as of March 24, 2023",
"Corporate Presentation current as of March 24, 2023"
03/16/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights"
01/06/2023 8-K Investor presentation
Docs: "Corporate Presentation current as of January 6, 2023"
01/04/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "Form of Common Stock Warrant",
"Securities Purchase Agreement, by and among Comera Life Sciences Holdings, Inc. and the Purchasers defined therein",
"Registration Rights Agreement dated January 4, 2023, by and among Comera Life Sciences Holdings, Inc. and the Purchasers defined therein",
"Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules WOBURN, Mass.—January 4, 2023— Comera Life Sciences Holdings, Inc . , a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private placement to existing stockholders, of 2,406,242 units, at a purchase price of $1.48 per unit, with each unit consisting of one share of the Company's common stock and one five-year warrant to purchase two shares of the Company's common stock at an exercise price of $1.23 per share, pursuant to the terms of a Securities Purchase Agreement entered into on January 2, 2023. Gross proceeds from the private placement of approximately $3.6 mill..."
11/23/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/02/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Audited financial statements of Legacy Comera as of and for the years ended December 31, 2021 and 2020",
"Consent of Independent Registered Public Accounting Firm",
"Audited financial statements of Legacy Comera as of and for the years ended December 31, 2021 and 2020"
08/31/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
07/29/2022 8-K Quarterly results
06/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Letter Agreement by and between Comera Life Sciences Holdings, Inc. and Michael Campbell"
05/25/2022 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy